Oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate

Oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate – evidence summary (ES3)
Information type: Evidence summaries
Source: National Institute for Health and Care Excellence
Specialities: Endocrine system disorders
Summary
Review suggests this may present an alternative treatment option for oestrogen deficiency symptoms in postmenopausal women for whom treatment with a progestin-containing therapy is not suitable. However, there are limited data on rare adverse events and active comparator lacking.
UKMi comment
Conjugated oestrogens and bazedoxifene modified release tablets (Duavive), were launched in the UK in July 2016. They are licensed for treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate.
Related links:

Oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate – evidence summary (ES3)